智通财经APP获悉，康方生物(09926)午前涨超10%，截至发稿，涨10.24%，报138.9港元，成交额15.06亿港元。
消息面上，7月16日，据康方生物官微消息，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方®(通用名：依沃西单抗注射液)用于一线治疗晚期转移性结直肠癌(pMMR/MSS型 mCRC)的注册性III期临床研究(AK112-312/HARMONi-GI6)已完成首例患者入组。这项针对mCRC一线治疗的随机、对照、多中心III期临床试验，是公司推动依沃西疗法攻克全球巨大临床未决需求的行动之一，彰显了公司对依沃西突破性临床价值潜力的强大信心，也是依沃西持续构建全球领先优势的重要举措。
依沃西方案的初步研究数据优于现有标准治疗的数据，以及既往披露的PD-1免疫检查点抑制剂的相关数据，这提示依沃西联合方案具有的潜在突破性临床价值，有望填补这类患者的免疫治疗空白。注册性III期研究AK112-312/HARMONi-GI6的启动，将进一步验证依沃西联合化疗在该患者群体中的优越性，有望成为MSS/pMMR型mCRC患者全新且高效的一线免疫治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.